Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Amgen has agreed to acquire privately held biotech Teneobio for as much as $2.5 billion in a deal meant to broaden the big biotech’s ability to develop antibody drugs for cancer and potentially other diseases.